Exclusive IP Sale: Nasally Applied Multivalent COVID + Flu Vaccine Platform
Clinically validated in animal models, filed with USPTO — available now for outright acquisition.
Request NDA & Data Room Access
Innovative Nasal Vaccine Platform
Our proprietary vaccine technology delivers multivalent protection against both COVID-19 and influenza through a nasal dry powder/spray format.
Key Advantages:
- Ease of administration: No needles, simple nasal delivery.
- Enhanced immunity: Targets mucosal pathways for stronger frontline defense.
- Patient compliance: Convenient, non-invasive, and suitable for mass immunization.
- Dual protection: Combines COVID-19 and flu antigens in a single formulation.
Preclinical Data
Validated in Animal Models
Our vaccine has demonstrated robust efficacy and safety in preclinical animal studies.
Highlights
- Strong immune response across multiple models.
- Excellent tolerability profile.
- Demonstrated protection against viral challenge.
Confidential Data Access:
Detailed study results are available under NDA.
Commercial Opportunity
Outright Sale of IP
This is a direct sale of intellectual property. The seller will not be involved in further research or development.
Benefits to Acquirer
- Full exclusivity and control.
- Freedom to advance clinical development and commercialization.
- Potential to establish durable monopolies through new filings on improvements
- Access to a global market for dual-protection nasal vaccines.
INTELLECTUAL PROPERTY
Patent Protection
- Filed with the USPTO (application number and filing date available upon request).
- Divisional filings possible within the USA.
- Acquirer retains full rights to pursue new patents on improvements not described in the original filing.
Opportunity:
Secure exclusive ownership of a foundational nasal vaccine platform with clear pathways for expansion.
